EuroVacc Foundation is a non-profit organization created in 2002, building on the research program “European Vaccine Effort Against HIV/AIDS” funded by the European Commission.
EuroVacc’s core activity
EuroVacc’s core activity is to facilitate the development of HIV vaccine candidates through early clinical trials, to enable early identification of the promising vaccine candidates and eliminate candidates unlikely to succeed in the clinic, with the ultimate goal to reduce the risks in advance of large development investments being made and accelerate the advancement of the promising candidates to large clinical trials.
EuroVacc’s primary objectives
Promote HIV vaccine research
To promote HIV vaccine research by bridging the strength of academic research groups with industrial expertise
Facilitate and support phase I & II clinical trials in Europe
To facilitate and support phase I & II clinical trials in Europe to expedite translational research from discovery to clinical development;
Partner with other international initiative
To partner with other international initiatives and industry for down-stream development and phase IIb/III trials.
Also see our International collaborations. Promoting collaboration with international stakeholders in the HIV and other infectious diseases fields is a central theme in EuroVacc’s mission, in order to broaden the discovery program and advance the product and clinical development of the most promising vaccine candidates.